Vinay Prasad, the U.S. Food and Drug Administration's chief medical and science officer, has left the health regulator, the U.S. Department of Health and Human Services, which oversees the FDA, said on Tuesday, confirming an earlier news report.
"Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," an HHS spokesperson said in an emailed statement to Reuters.
"We thank him for his service and the many important reforms he was able to achieve in his time at FDA."
Endpoints News first reported about Prasad's departure, saying it came after a number of controversial decisions by the FDA regarding a gene therapy drug for the treatment of Duchenne muscular dystrophy manufactured by Sarepta Therapeutics .
The agency first halted shipments of the drug, called Elevidys, after the deaths of some recipients but rescinded the suspension on Monday.
Prasad was named as the health regulator's chief medical and science officer in June, STAT News reported.
In May, the FDA named Prasad, an oncologist who previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research.
"Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," an HHS spokesperson said in an emailed statement to Reuters.
"We thank him for his service and the many important reforms he was able to achieve in his time at FDA."
Endpoints News first reported about Prasad's departure, saying it came after a number of controversial decisions by the FDA regarding a gene therapy drug for the treatment of Duchenne muscular dystrophy manufactured by Sarepta Therapeutics .
The agency first halted shipments of the drug, called Elevidys, after the deaths of some recipients but rescinded the suspension on Monday.
Prasad was named as the health regulator's chief medical and science officer in June, STAT News reported.
In May, the FDA named Prasad, an oncologist who previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research.
